Utkarsh Goel

19PUBLICATIONS
76CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsTe urupare me te whai wāhi Māori ki te mātauranga (Māori responsiveness and engaged education)Autoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Apr 23, 2026
Functional high-risk phenotype predicts poor survival in multiple myeloma independent of front-line treatment: A secondary analysis of CIBMTR data.

|Mar 28, 2026
Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Andrew J Portuguese, James A Davis, Shahzad Raza

|Nov 28, 2025
The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Aimaz Afrough, Danai Dima, Beatrice Razzo

|Jun 25, 2025
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Danai Dima, Mariola A Vazquez-Martinez, James A Davis

|May 09, 2025
Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Oren Pasvolsky, Danai Dima, Lei Feng

|Apr 13, 2025
Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: 14-Year Experience of an Academic Center.

Danai Dima, Utkarsh Goel, Fauzia Ullah

Pageof 4

Frequent Collaborators

11 joint publications

Faiz Anwer

10 joint publications

Jack Khouri

7 joint publications

Shahzad Raza

6 joint publications

Shaji Kumar